Biallelic variants in AGTPBP1, involved in tubulin deglutamylation, are associated with cerebellar degeneration and motor neuropathy.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
09 2019
Historique:
received: 26 10 2018
accepted: 26 03 2019
revised: 16 03 2019
pubmed: 13 4 2019
medline: 13 6 2020
entrez: 13 4 2019
Statut: ppublish

Résumé

The ATP/GTP-Binding Protein 1 (AGTPBP1) gene (OMIM *606830) catalyzes deglutamylation of polyglutamylated proteins, and its deficiency manifests by cerebellar ataxia and peripheral neuropathy in mice and lower motor neuron-like disease in sheep. In the mutant mice, cerebellar atrophy due to Purkinje cell degeneration is observed, likely due to increased tubulin polyglutamylation in affected brain areas. We report two unrelated individuals who presented with early onset cerebellar atrophy, developmental arrest with progressive muscle weakness, and feeding and respiratory difficulties, accompanied by severe motor neuronopathy. Whole exome sequencing followed by segregation analysis in the families and cDNA studies revealed deleterious biallelic variants in the AGTPBP1 gene. We conclude that complete loss-of-function of AGTPBP1 in humans, just like in mice and sheep, is associated with cerebellar and motor neuron disease, reminiscent of Pontocerebellar Hypoplasia Type 1 (PCH1).

Identifiants

pubmed: 30976113
doi: 10.1038/s41431-019-0400-y
pii: 10.1038/s41431-019-0400-y
pmc: PMC6777529
doi:

Substances chimiques

Tubulin 0
AGTPBP1 protein, human EC 3.4.16.4
Serine-Type D-Ala-D-Ala Carboxypeptidase EC 3.4.16.4
GTP-Binding Proteins EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1419-1426

Références

van Dijk T, Baas F, Barth PG, Poll-The BT. What’s new in pontocerebellar hypoplasia? An update on genes and subtypes. Orphanet J Rare Dis. 2018;13:92.
doi: 10.1186/s13023-018-0826-2
Norman RM. Cerebellar hypoplasia in Werdnig-Hoffmann disease. Arch Dis Child. 1961;36:96–101.
doi: 10.1136/adc.36.185.96
Goutières F, Aicardi J, Farkas E. Anterior horn cell disease associated with pontocerebellar hypoplasia in infants. J Neurol Neurosurg Psychiatry. 1977;40:370–8.
doi: 10.1136/jnnp.40.4.370
Kamoshita S, Takei Y, Miyao M, Yanagisawa M, Kobayashi S, Saito K. Pontocerebellar hypoplasia associated with infantile motor neuron disease (Norman’s disease). Pediatr Pathol. 1990;10:133–42.
doi: 10.3109/15513819009067102
Wan J, Yourshaw M, Mamsa H, Rudnik-Schöneborn S, Menezes MP, Hong JE, et al. Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration. Nat Genet. 2012;44:704–8.
doi: 10.1038/ng.2254
Rudnik-Schöneborn S, Senderek J, Jen JC, Houge G, Seeman P, Puchmajerová A, et al. Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations. Neurology. 2013;80:438–46.
doi: 10.1212/WNL.0b013e31827f0f66
Eggens VR, Barth PG, Niermeijer JM, Berg JN, Darin N, Dixit A, et al. EXOSC3 mutations in pontocerebellar hypoplasia type 1: novel mutations and genotype-phenotype correlations. Orphanet J Rare Dis. 2014;9:23.
doi: 10.1186/1750-1172-9-23
Boczonadi V, Müller JS, Pyle A, Munkley J, Dor T, Quartararo J. et al. EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular atrophy and cerebellar hypoplasia. Nat Commun. 2014;5:4287
doi: 10.1038/ncomms5287
Burns DT, Donkervoort S, Müller JS, Knierim E, Bharucha-Goebel D, Faqeih EA, et al. Variants in EXOSC9 disrupt the RNA exosome and result in cerebellar atrophy with spinal motor neuronopathy. Am J Hum Genet. 2018;102:858–73.
doi: 10.1016/j.ajhg.2018.03.011
Renbaum P, Kellerman E, Jaron R, Geiger D, Segel R, Lee M, et al. Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene. Am J Hum Genet. 2009;85:281–9.
doi: 10.1016/j.ajhg.2009.07.006
Gonzaga-Jauregui C, Lotze T, Jamal L, Penney S, Campbell IM, Pehlivan D, et al. Mutations in VRK1 associated with complex motor and sensory axonal neuropathy plus microcephaly. JAMA Neurol. 2013;70:1491–8.
pubmed: 24126608 pmcid: 4039291
Stoll M, Teoh H, Lee J, Reddel S, Zhu Y, Buckley M, et al. Novel motor phenotypes in patients with VRK1 mutations without pontocerebellar hypoplasia. Neurology. 2016;87:65–70.
doi: 10.1212/WNL.0000000000002813
Wan J, Steffen J, Yourshaw M, Mamsa H, Andersen E, Rudnik-Schöneborn S, et al. Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. Brain. 2016;139:2877–90.
doi: 10.1093/brain/aww212
Abrams AJ, Hufnagel RB, Rebelo A, Zanna C, Patel N, Gonzalez MA, et al. Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. Nat Genet. 2015;47:926–32.
doi: 10.1038/ng.3354
Vinograd-Byk H, Sapir T, Cantarero L, Lazo PA, Zeligson S, Lev D, et al. The spinal muscular atrophy with pontocerebellar hypoplasia gene VRK1 regulates neuronal migration through an amyloid-β precursor protein-dependent mechanism. J Neurosci. 2015;35:936–42.
doi: 10.1523/JNEUROSCI.1998-14.2015
Janer A, Prudent J, Paupe V, Fahiminiya S, Majewsky J, Sgarioto N, et al. SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol Med. 2016;8:1019–38.
doi: 10.15252/emmm.201506159
Ta-Shma A, Zhang K, Salimova E, Zernecke A, Sieiro-Mosti D, Stegner D, et al. Congenital valvular defects associated with deleterious mutations in the PLD1 gene. J Med Genet. 2017;54:278–86.
doi: 10.1136/jmedgenet-2016-104259
Rogowski K, van Dijk J, Magiera MM, Bosc C, Deloulme JC, Bosson A, et al. A family of protein-deglutamylating enzymes associated with neurodegeneration. Cell. 2010;143:564–78.
doi: 10.1016/j.cell.2010.10.014
Harris A, Morgan JI, Pecot M, Soumare A, Osborne A, Soares HD. Regenerating motor neurons express Nna1, a novel ATP/GTP-binding protein related to zinc carboxypeptidases. Mol Cell Neurosci. 2000;16:578–96.
doi: 10.1006/mcne.2000.0900
Fukushima N, Furuta D, Hidaka Y, Moriyama R, Tsujiuchi T. Post-translational modifications of tubulin in the nervous system. J Neurochem. 2009;109:683–93.
doi: 10.1111/j.1471-4159.2009.06013.x
Fernandez-Gonzalez A, La Spada AR, Treadaway J, Higdon JC, Harris BS, Sidman RL, et al. Purkinje cell degeneration (pcd) phenotypes caused by mutations in the axotomy-induced gene, Nna1. Science. 2002;295:1904–6.
doi: 10.1126/science.1068912
Wu HY, Wang T, Li L, Correia K, Morgan JI. A structural and functional analysis of Nna1 in Purkinje cell degeneration (pcd) mice. FASEB J. 2012;26:4468–80.
doi: 10.1096/fj.12-205047
Wu HY, Rong Y, Correia K, Min J, Morgan JI. Comparison of the enzymatic and functional properties of three cytosolic carboxypeptidase family members. J Biol Chem. 2015;290:1222–32.
doi: 10.1074/jbc.M114.604850
Anderson PD, Parton KH, Collett MG, Sargison ND, Jolly RD. A lower motor neuron disease in newborn Romney lambs. N Z Vet J. 1999;47:112–4.
doi: 10.1080/00480169.1999.36125
Zhao X, Onteru SK, Dittmer KE, Parton K, Blair HT, Rothschild MF, et al. A missense mutation in AGTPBP1 was identified in sheep with a lower motor neuron disease. Heredity. 2012;109:156–62.
doi: 10.1038/hdy.2012.23
Monies D, Abouelhoda M, AlSayed M, Alhassnan Z, Alotaibi M, Kayyali H, et al. The landscape of genetic diseases in Saudi Arabia based on the first 1000 diagnostic panels and exomes. Hum Genet. 2017;136:921–39.
doi: 10.1007/s00439-017-1821-8
Kitano S, Kino Y, Yamamoto Y, Takitani M, Miyoshi J, Ishida T, et al. Bioinformatics data mining approach suggests coexpression of AGTPBP1 with an ALS-linked gene C9orf72. J Cent Nerv Syst Dis. 2015;7:15–26.
doi: 10.4137/JCNSD.S24317

Auteurs

Ruth Sheffer (R)

Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, 9112001, Jerusalem, Israel. Ruthsh@hadassah.org.il.

Michal Gur (M)

Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, 9112001, Jerusalem, Israel.

Rebecca Brooks (R)

Pediatric Intensive Unit, Department of Pediatrics, Mount Scopus Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Somaya Salah (S)

Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, 9112001, Jerusalem, Israel.

Muhannad Daana (M)

Child Development Centers, Clalit and Maccabi Health Care Services, Jerusalem, Israel.

Nitay Fraenkel (N)

Department of Respiratory Rehabilitation, Alyn Hospital, Jerusalem, Israel.

Eli Eisenstein (E)

Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Malcolm Rabie (M)

Institute of Child Neurology, Schneider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel.

Yoram Nevo (Y)

Institute of Child Neurology, Schneider Children's Medical Center of Israel, Tel Aviv University, Tel Aviv, Israel.

Chaim Jalas (C)

Bonei Olam, Center for Rare Jewish Genetic Diseases, Brooklyn, NY, USA.

Orly Elpeleg (O)

Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, 9112001, Jerusalem, Israel.
Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Shimon Edvardson (S)

Monique and Jacques Roboh Department of Genetic Research, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Pediatric Neurology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Tamar Harel (T)

Department of Genetic and Metabolic Diseases, Hadassah-Hebrew University Medical Center, 9112001, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH